![]() |
Lung Cancer |
Free Subscription
1 AJR Am J Roentgenol |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO Lung Cancer is free of charge.
A Meaningful Stride Toward Precision Staging in Early-Stage Non-Small Cell Lung
Cancer.
AJR Am J Roentgenol. 2025 Jun 4. doi: 10.2214/AJR.25.33332.
PubMed
Primary low-grade salivary gland-type intraductal carcinoma of the lung with
CCDC6::RET fusion: Case presentation and literature review.
Am J Clin Pathol. 2025;163:877-882.
PubMed
Abstract available
The Bi-steric Inhibitor RMC-5552 Reduces mTORC1 Signaling and Growth in
Lymphangioleiomyomatosis.
Am J Respir Cell Mol Biol. 2025;72:643-652.
PubMed
Abstract available
Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated
advanced non-small cell lung cancer with MET overexpression and/or amplification
following disease progression on osimertinib: primary results from the phase II
SAVANNAH s
Ann Oncol. 2025 May 22:S0923-7534(25)00157-7. doi: 10.1016/j.annonc.2025.
PubMed
Abstract available
Reply to Letter to the Editor "Lung cancer detection by electronic nose analysis
of exhaled breath: a multi-center prospective external validation study" by Liu
et al., G. Rocco, and Szarpak et al.
Ann Oncol. 2025 Jun 2:S0923-7534(25)00198-X. doi: 10.1016/j.annonc.2025.
PubMed
Thoracic Adipose Volume is Associated with Occult Nodal Disease and Disease-Free
Survival in Females with Clinically Node-Negative Non-Small Cell Lung Cancer.
Ann Surg Oncol. 2025 Jun 3. doi: 10.1245/s10434-025-17485.
PubMed
Abstract available
Clinical Significance of Tumor-Infiltrating Lymphocytes in Malignant Peritoneal
Mesothelioma: A Single-Center Study of 143 Cases.
Ann Surg Oncol. 2025;32:5051-5062.
PubMed
Abstract available
EGFR Mutation Rates Correlate with Age at Diagnosis and Tumor Characteristics in
Patients with Pulmonary Ground-Glass Opacities.
Ann Surg Oncol. 2025;32:4641-4649.
PubMed
Abstract available
Reassessing Efficacy: Understanding Failures in Lung Cancer Screening Despite
Low-Dose CT Protocol Adherence.
Ann Thorac Surg. 2025 May 28:S0003-4975(25)00448.
PubMed
Abstract available
The prognostic/ predictive value of the systematic inflammatory response in
patients receiving immunotherapy for non-small cell lung cancer: a systematic
review and meta-analysis.
BMC Cancer. 2025;25:994.
PubMed
Abstract available
Identification and validation of a DNA methylation-block prognostic model in
non-small cell lung cancer patients.
BMC Cancer. 2025;25:999.
PubMed
Abstract available
Cathepsin C correlates with M2 macrophage infiltration and regulates the tumor
growth and metastasis in non-small cell lung cancer.
BMC Cancer. 2025;25:1001.
PubMed
Abstract available
Re-resection of brain metastases - outcomes of an institutional cohort study and
literature review.
BMC Cancer. 2025;25:973.
PubMed
Abstract available
EGFR-mutated non-small cell lung cancer.
BMJ. 2025;389:r1154.
PubMed
Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated
advanced non-small cell lung cancer: multicentre, open label, randomised
controlled trial.
BMJ. 2025;389:e085680.
PubMed
Abstract available
Circulating tumor DNA dynamic variation predicts sotorasib efficacy in
KRASp.G12C-mutated advanced non-small cell lung cancer.
Cancer. 2025;131:e35917.
PubMed
Abstract available
Cancer Epidemiol Biomarkers Prev
Human Immunodeficiency Virus-Associated Differences in the Tumor Immune
Microenvironment of Lung, Breast, and Prostate Cancers.
Cancer Epidemiol Biomarkers Prev. 2025;34:860-867.
PubMed
Abstract available
WDR11-DT enhances radiosensitivity via promoting PARP1 degradation and homologous
recombination deficiency.
Cancer Lett. 2025;625:217757.
PubMed
Abstract available
Mutation of SMARCA4 Induces Cancer Cell-Intrinsic Defects in the Enhancer
Landscape and Resistance to Immunotherapy.
Cancer Res. 2025;85:1997-2013.
PubMed
Abstract available
The impact of BTK knockdown on lung adenocarcinoma growth and immune response.
Cancer Sci. 2025;116:1550-1564.
PubMed
Abstract available
Spatial Heterogeneity of PD-L1 Expression as a Biomarker for Third-Generation
EGFR-TKI Response in Advanced EGFR-Mutant NSCLC.
Cancer Sci. 2025;116:1648-1660.
PubMed
Abstract available
Permeable Lung Vasculature Creates Chemoresistant Endothelial Niche by Producing
SERPINE1 at Breast Cancer Metastatic Sites.
Cancer Sci. 2025;116:1604-1615.
PubMed
Abstract available
Somatic p53 mutations that are markedly overrepresented in lung cancer confer
resistance to ROS-induced cell death.
Carcinogenesis. 2025 Jun 3:bgaf027. doi: 10.1093.
PubMed
Abstract available
Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but
Worse Overall Survival in Advanced Non-Small Cell Lung Cancer: a Lung-MAP Study.
Clin Cancer Res. 2025 Jun 4. doi: 10.1158/1078-0432.CCR-24-3658.
PubMed
Abstract available
ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced
NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical
Trials.
Clin Cancer Res. 2025;31:2162-2172.
PubMed
Abstract available
Pulmonary Lymphangitis Carcinomatosis in Rapid Progressive Recurrent
Pheochromocytoma: A Case Exhibiting the Peer Diagnostic Value of 99mTc-FAPI-46
and 99mTc-HYNIC-Octreotide Scans.
Clin Nucl Med. 2025;50:e417-e418.
PubMed
Abstract available
Prognostic Value of 18F-FDG PET/CT in Neoadjuvant PD-1 Inhibitor-treated NSCLC: A
Five-year Follow-up Study.
Clin Nucl Med. 2025;50:577-587.
PubMed
Abstract available
PSMA and FDG PET/CT Findings for Differential Diagnosis of Bone Metastasis in a
Patient With Synchronous Small-cell Lung Cancer and Prostate Cancer.
Clin Nucl Med. 2025 Jun 5. doi: 10.1097/RLU.0000000000005915.
PubMed
Abstract available
Concurrent spread through air spaces in dominant tumours impacts prognosis in
synchronous multiple primary lung adenocarcinoma.
Eur J Cardiothorac Surg. 2025;67:ezaf163.
PubMed
Abstract available
Efficacy and safety of autologous CIK cell therapy plus Toripalimab with or
without chemotherapy in advanced NSCLC: A phase II study.
Int J Cancer. 2025;157:549-558.
PubMed
Abstract available
A prognostic PET radiomic model for risk stratification in non-small cell lung
cancer: integrating radiogenomics and clinical features to predict survival and
uncover tumor biology insights.
J Cancer Res Clin Oncol. 2025;151:180.
PubMed
Abstract available
Fluorodeoxyglucose (FDG) PET/CT imaging analysis and clinical treatment
evaluation in patients with SMARCA4-deficient tumors: case reports of four
patients.
J Cancer Res Clin Oncol. 2025;151:182.
PubMed
Abstract available
Hyaluronan network remodeling by ZEB1 and ITIH2 enhances the motility and
invasiveness of cancer cells.
J Clin Invest. 2025;135:e180570.
PubMed
Abstract available
Tumor microenvironment of non-small cell lung cancer impairs immune cell function
among people with HIV.
J Clin Invest. 2025 Jun 3:e177310. doi: 10.1172/JCI177310.
PubMed
Abstract available
Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected
Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized,
Phase III Trial.
J Clin Oncol. 2025 May 30:JCO2401681. doi: 10.1200/JCO-24-01681.
PubMed
Abstract available
Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small-Cell Lung Cancer.
J Clin Oncol. 2025 Jun 2:101200JCO2500883. doi: 10.1200/JCO-25-00883.
PubMed
Abstract available
RE: Efficacy and safety of personalized optimal programmed cell death 1 ligand
combinations in advanced non-small cell lung cancer: a network meta-analysis.
J Natl Cancer Inst. 2025 Jun 6:djaf132. doi: 10.1093.
PubMed
Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic
Non-small Cell Lung Cancer Treated With First-Line Nivolumab Plus Ipilimumab
Versus Chemotherapy in CheckMate 227 Part 1.
J Thorac Oncol. 2025 Jun 3:S1556-0864(25)00749.
PubMed
Abstract available
Advances in lung cancer basic and translational research in 2025 - Overview and
perspectives focusing on non-small cell lung cancer.
J Thorac Oncol. 2025 Jun 3:S1556-0864(25)00754.
PubMed
Abstract available
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus
atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised,
multicentre, open-label, phase 3 trial.
Lancet. 2025 May 30:S0140-6736(25)01011-6. doi: 10.1016/S0140-6736(25)01011.
PubMed
Abstract available
Corrigendum to "A reproducibility study on invasion in small pulmonary
adenocarcinoma according to the WHO and a modified classification, supported by
biomarkers" [Lung Cancer 199 (2025) 108060].
Lung Cancer. 2025;204:108488.
PubMed
A Reply to comment on "Long-term outcomes of neoadjuvant gefitinib in resectable
stage II-IIIA non-small cell lung cancer: A phase II, prospective cohort study".
Lung Cancer. 2025;204:108537.
PubMed
Delayed central nervous system progression with atezolizumab plus chemotherapy in
extensive-stage small-cell lung cancer (LU23-15).
Lung Cancer. 2025;204:108536.
PubMed
Comment on "Long-term outcomes of neoadjuvant gefitinib in resectable stage
II-IIIA non-small cell lung cancer: A phase II, prospective cohort study".
Lung Cancer. 2025;204:108515.
PubMed
Development and clinical validation of a prognostic algorithm for stroma-tumor
ratio quantification in non-small cell lung cancer.
Lung Cancer. 2025;205:108613.
PubMed
Abstract available
ARID1A mutational status in non-small cell lung cancer: from molecular pathology
to clinical implications with a focus on the relationships with EGFR.
Lung Cancer. 2025;205:108594.
PubMed
Abstract available
Intracranial and systemic progression on amivantamab in platinum-treated
epidermal growth factor receptor exon 20 insertion-mutated advanced non-small
cell lung cancer.
Lung Cancer. 2025;205:108579.
PubMed
Abstract available
Investigation of cardiotoxicity in patients treated with osimertinib: findings
from the OSI-FACT study.
Lung Cancer. 2025;204:108589.
PubMed
Abstract available
Risk of lung injury with immune checkpoint inhibitors after talc pleurodesis: A
retrospective study.
Lung Cancer. 2025;204:108590.
PubMed
Abstract available
Intrathecal nivolumab and IL-2 for treatment of leptomeningeal metastases in
EGFR-mutated lung adenocarcinoma.
Lung Cancer. 2025;204:108586.
PubMed
Abstract available
Neoadjuvant immunotherapy in early-stage NSCLC: navigating biomarker dilemmas and
special population challenges.
Lung Cancer. 2025;204:108588.
PubMed
Abstract available
Unusual relapse dynamics in EGFR-mutated lung adenocarcinoma uncovered by genomic
profiling: Insights from a case report.
Lung Cancer. 2025;204:108587.
PubMed
Abstract available
Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression
among patients with unresectable, stage III NSCLC treated with CRT --> durvalumab
in Canada: The RELEVANCE study.
Lung Cancer. 2025;204:108583.
PubMed
Abstract available
A prospective study on clinicians' attitudes and survival outcomes for patients
with advanced NSCLC and poor performance status in the immunotherapy era: PICASO
(GOIRC-04-2020).
Lung Cancer. 2025;204:108580.
PubMed
Abstract available
Equalizing prognostic disparities in KRAS-mutated stage III NSCLC patients:
addition of durvalumab to combined chemoradiotherapy improves survival.
Lung Cancer. 2025;204:108573.
PubMed
Abstract available
Midazolam with fentanyl for endobronchial ultrasound-guided transbronchial needle
aspiration: a randomized, double-blind, phase III study.
Lung Cancer. 2025;204:108556.
PubMed
Abstract available
Antibody-drug conjugate components in association with the incidence of
ADC-related interstitial lung disease: A systematic review and meta-analysis.
Lung Cancer. 2025;204:108559.
PubMed
Abstract available
Comprehensive molecular profiling of advanced NSCLC using NGS: Prevalence of
druggable mutations and clinical trial opportunities in the ATLAS study.
Lung Cancer. 2025;204:108550.
PubMed
Abstract available
Multimodality treatment in synchronous oligometastatic NSCLC: Analysis of the
ETOP CHESS trial.
Lung Cancer. 2025;204:108553.
PubMed
Abstract available
Whole slide image-level classification of malignant effusion cytology using
clustering-constrained attention multiple instance learning.
Lung Cancer. 2025;204:108552.
PubMed
Abstract available
EGFR mutation testing across the osimertinib clinical program.
Lung Cancer. 2025;204:108549.
PubMed
Abstract available
Impact of immune-related adverse event severity on overall survival in patients
with advanced NSCLC receiving immune checkpoint inhibitors therapy, with a focus
on combination regimens.
Lung Cancer. 2025;204:108555.
PubMed
Abstract available
Elucidating the Role of FASN in Lung Cancer Stem Cells in Sensitive and Resistant
EGFR-Mutated Non-Small Cell Lung Cancer Cells.
Lung Cancer (Auckl). 2025;16:57-72.
PubMed
Abstract available
Navigational Bronchoscopy or Transthoracic Needle Biopsy for Lung Nodules.
N Engl J Med. 2025;392:2100-2112.
PubMed
Abstract available
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer.
N Engl J Med. 2025 Jun 2. doi: 10.1056/NEJMoa2502931.
PubMed
Abstract available
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy.
N Engl J Med. 2025 Jun 2. doi: 10.1056/NEJMoa2502099.
PubMed
Abstract available
Perioperative durvalumab plus chemotherapy plus new agents for resectable
non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial.
Nat Med. 2025 May 31. doi: 10.1038/s41591-025-03746.
PubMed
Abstract available
Methylation of RBM39 by PRMT6 enhances resistance to Indisulam in non-small cell
lung cancer by promoting alternative splicing of proto-oncogenes.
PLoS Biol. 2025;23:e3002846.
PubMed
Abstract available
XLLC-Net: A lightweight and explainable CNN for accurate lung cancer
classification using histopathological images.
PLoS One. 2025;20:e0322488.
PubMed
Abstract available
Performance of volume and diameter thresholds in malignancy prediction of solid
nodules in lung cancer screening.
Thorax. 2025 Jun 2:thorax-2024-222086. doi: 10.1136/thorax-2024-222086.
PubMed
Abstract available
Comparison of volume-based and diameter-based assessment of solid nodules in lung
cancer screening.
Thorax. 2025 Jun 2:thorax-2025-223295. doi: 10.1136/thorax-2025-223295.
PubMed
Thank you for your interest in scientific medicine.